Loading...
Market
WHO Withdraws Takeda's Dengue Vaccine Prequalification by 2025
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official WHO announcements or safety alerts
Story
WHO Prequalifies Takeda's New Second Dengue Vaccine Amid Rising Outbreaks
May 15, 2024, 05:16 PM
The World Health Organization (WHO) has prequalified Takeda Pharmaceuticals' new dengue vaccine, marking it as the second dengue vaccine approved amid rising outbreaks in the Americas. The WHO recommends the vaccine for use in children aged 6 to 16 years in areas with high dengue burden and transmission intensity. This new vaccine aims to boost the fight against dengue fever, a vector-borne disease transmitted by mosquitoes, with over 100-400 million cases reported worldwide each year.
View original story
Similar markets
Less than 20 countries • 33%
20-50 countries • 34%
More than 50 countries • 33%
Below 50% effectiveness • 33%
50-75% effectiveness • 34%
Above 75% effectiveness • 33%
Below 20% market share • 33%
20-40% market share • 34%
Above 40% market share • 33%
Expansion of the project • 33%
Modification of the project • 33%
Termination of the project • 34%
